As the understanding of cancer biology expands, a wider array of treatment options has become available in the field of gynecologic cancer. Therapies that target specific molecular pathways are now being used. Drugs that target cancer angiogenesis, signal transduction, DNA repair, and immune evasion mechanisms are currently being used, in addition to or in lieu of traditional chemotherapy, to achieve more personalized treatment of each patient and their unique disease. These therapies may lead to improved survival outcomes and quality of life during treatment and during remission.
Keywords: Antiangiogenic therapy; Chemotherapy; Immunotherapy; PARP inhibitors; Targeted therapy; Toxicity; Tyrosine kinase inhibitors (TKI).
Published by Elsevier Inc.